Literature DB >> 23897787

Metabolic remodeling in chronic heart failure.

Jing Wang1, Tao Guo.   

Abstract

Although the management of chronic heart failure (CHF) has made enormous progress over the past decades, CHF is still a tremendous medical and societal burden. Metabolic remodeling might play a crucial role in the pathophysiology of CHF. The characteristics and mechanisms of metabolic remodeling remained unclear, and the main hypothesis might include the changes in the availability of metabolic substrate and the decline of metabolic capability. In the early phases of the disease, metabolism shifts toward carbohydrate utilization from fatty acids (FAs) oxidation. Along with the progress of the disease, the increasing level of the hyperadrenergic state and insulin resistance cause the changes that shift back to a greater FA uptake and oxidation. In addition, a growing body of experimental and clinical evidence suggests that the improvement in the metabolic capability is likely to be more significant than the selection of the substrate.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23897787      PMCID: PMC3735968          DOI: 10.1631/jzus.B1300137

Source DB:  PubMed          Journal:  J Zhejiang Univ Sci B        ISSN: 1673-1581            Impact factor:   3.066


  74 in total

1.  Eplerenone in patients with systolic heart failure and mild symptoms.

Authors:  Faiez Zannad; John J V McMurray; Henry Krum; Dirk J van Veldhuisen; Karl Swedberg; Harry Shi; John Vincent; Stuart J Pocock; Bertram Pitt
Journal:  N Engl J Med       Date:  2010-11-14       Impact factor: 91.245

Review 2.  The role of PGC-1 coactivators in aging skeletal muscle and heart.

Authors:  Lloye M Dillon; Adriana P Rebelo; Carlos T Moraes
Journal:  IUBMB Life       Date:  2012-01-25       Impact factor: 3.885

Review 3.  No low-fat diet for the failing heart?

Authors:  Heinrich Taegtmeyer; Kalpana Ballal
Journal:  Circulation       Date:  2006-11-14       Impact factor: 29.690

4.  2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation.

Authors:  Sharon Ann Hunt; William T Abraham; Marshall H Chin; Arthur M Feldman; Gary S Francis; Theodore G Ganiats; Mariell Jessup; Marvin A Konstam; Donna M Mancini; Keith Michl; John A Oates; Peter S Rahko; Marc A Silver; Lynne Warner Stevenson; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2009-04-14       Impact factor: 24.094

Review 5.  Metabolic remodelling in human heart failure.

Authors:  Helena Tuunanen; Juhani Knuuti
Journal:  Cardiovasc Res       Date:  2011-03-03       Impact factor: 10.787

6.  Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy.

Authors:  S Neubauer; M Horn; M Cramer; K Harre; J B Newell; W Peters; T Pabst; G Ertl; D Hahn; J S Ingwall; K Kochsiek
Journal:  Circulation       Date:  1997-10-07       Impact factor: 29.690

Review 7.  Energy metabolism in heart failure.

Authors:  Renée Ventura-Clapier; Anne Garnier; Vladimir Veksler
Journal:  J Physiol       Date:  2003-12-05       Impact factor: 5.182

Review 8.  In search of new therapeutic targets and strategies for heart failure: recent advances in basic science.

Authors:  Ajay M Shah; Douglas L Mann
Journal:  Lancet       Date:  2011-08-20       Impact factor: 79.321

Review 9.  Optimization of cardiac metabolism in heart failure.

Authors:  Tomohisa Nagoshi; Michihiro Yoshimura; Giuseppe M C Rosano; Gary D Lopaschuk; Seibu Mochizuki
Journal:  Curr Pharm Des       Date:  2011-12       Impact factor: 3.116

Review 10.  Modification of myocardial substrate use as a therapy for heart failure.

Authors:  Khalid Abozguia; Kieran Clarke; Leong Lee; Michael Frenneaux
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2006-09
View more
  5 in total

Review 1.  COUP-TFII revisited: Its role in metabolic gene regulation.

Authors:  Usman M Ashraf; Edwin R Sanchez; Sivarajan Kumarasamy
Journal:  Steroids       Date:  2018-11-24       Impact factor: 2.668

2.  L-Carnitine, but not coenzyme Q10, enhances the anti-osteoporotic effect of atorvastatin in ovariectomized rats.

Authors:  Hussam A S Murad
Journal:  J Zhejiang Univ Sci B       Date:  2016-01       Impact factor: 3.066

3.  Trimetazidine attenuates pressure overload-induced early cardiac energy dysfunction via regulation of neuropeptide Y system in a rat model of abdominal aortic constriction.

Authors:  Ailan Chen; Wanglin Li; Xinyu Chen; Yuechun Shen; Wenjun Dai; Qi Dong; Xinchun Li; Caiwen Ou; Minsheng Chen
Journal:  BMC Cardiovasc Disord       Date:  2016-11-17       Impact factor: 2.298

Review 4.  Chronic Heart Failure: Clinical Implications of Iron Homeostasis Disturbances Revisited.

Authors:  Leonardo P Suciadi; Joshua Henrina; Iwan Cahyo Santosa Putra; Irvan Cahyadi; Hoo Felicia Hadi Gunawan
Journal:  Cureus       Date:  2022-01-13

Review 5.  Cardiotoxicity with vascular endothelial growth factor inhibitor therapy.

Authors:  Rhian M Touyz; Joerg Herrmann
Journal:  NPJ Precis Oncol       Date:  2018-05-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.